IGA NEPHROPATHY
Clinical trials for IGA NEPHROPATHY explained in plain language.
Never miss a new study
Get alerted when new IGA NEPHROPATHY trials appear
Sign up with your email to follow new studies for IGA NEPHROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for kidney disease: atrasentan shows promise in reducing protein leak
Disease control CompletedThis study tested a drug called atrasentan in 54 adults with IgA nephropathy, a kidney disease. All participants were already on standard treatments including SGLT2 inhibitors. The goal was to see if atrasentan could reduce protein in the urine, a sign of kidney damage, compared …
Matched conditions: IGA NEPHROPATHY
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 04:51 UTC
-
New hope for kidney disease: drug trial targets IgA nephropathy
Disease control CompletedThis study tested a new drug, HR19042, in 316 adults with IgA nephropathy, a kidney disease. The goal was to see if the drug can reduce protein in the urine and protect kidney function compared to a placebo. The trial is now complete, and results will help determine the best dose…
Matched conditions: IGA NEPHROPATHY
Phase: PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 04:47 UTC
-
New drug shows promise in slowing kidney disease progression
Disease control CompletedThis study tested a drug called iptacopan (LNP023) in 518 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The goal was to see if the drug could reduce protein in the urine and slow the loss of kidney function compared to a placebo. All participants …
Matched conditions: IGA NEPHROPATHY
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 04:37 UTC
-
New drug targets kidney disease in early trial
Disease control CompletedThis study tested a new drug called ARO-C3 in healthy volunteers and people with kidney diseases caused by an overactive immune system (C3 Glomerulopathy and IgA Nephropathy). The main goal was to check the drug's safety and how it moves through the body. Participants received on…
Matched conditions: IGA NEPHROPATHY
Phase: PHASE1, PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated May 18, 2026 12:12 UTC
-
Can early steroids save kidneys in IgA nephropathy?
Disease control CompletedThis study looked at whether adding early steroid treatment to standard blood pressure medication helps people with IgA nephropathy who have severe kidney damage. 62 adults took part. The goal was to see if the combination could prevent kidney function from getting worse over two…
Matched conditions: IGA NEPHROPATHY
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated May 18, 2026 12:08 UTC